Frequently Asked Questions Is burning at the injection site normal with semaglutide
Ecnoglutide injection was approved by China's National Medical Products Administration (NMPA) in January 2026 for the treatment of adult type 2 diabetes, and its marketing authorisation application for adult chronic weight management has been accepted by China's NMPA
Rikjer, J
Of more than 260,000 ingestions in the 10-year period, about 4,000 children were hospitalized, and a handful needed to be put on ventilators
Important patient safety considerations include: GLP-1 receptor agonists are currently licensed only for type 2 diabetes and, for specific products, weight managementnot for neurological conditions Common side effects include nausea, vomiting, diarrhoea, and constipation, which usually improve over time Patients should seek urgent medical help for symptoms suggestive of pancreatitis (severe, persistent abdominal pain, often radiating to the back, with or without vomiting) Gallbladder problems including gallstones and inflammation may occur Risk of hypoglycaemia is increased when used with insulin or sulfonylureas Diabetic retinopathy complications may occur with semaglutide, particularly with rapid improvement in blood glucose control [26] [27] Severe gastrointestinal side effects may lead to dehydration and acute kidney injury These medications are not recommended during pregnancy or breast-feeding [25] [1] Patients should report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app)
